Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 3, 2007

Ciphergen and Quest Diagnostics to Develop PAD Diagnostic

  • Quest Diagnostics accepted a second development plan from Ciphergen under their existing strategic alliance agreement. In addition to the current ovarian tumor triage test, Quest Diagnostics will now also assist Ciphergen in the development of a blood-based assay for the detection of peripheral artery disease (PAD).

    Ciphergen is working with Stanford University to develop a blood test that will help physicians in the diagnosis of PAD. Similar to cardiovascular disease, PAD is caused by the buildup of fat and cholesterol in the peripheral arteries and disrupts normal bloodflow leading to stenosis.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »